|
Study program
|
Treatment group
|
North America
|
Western Europe
|
Australia/South Africa
|
Japan
|
Asia
|
Eastern Europe/Russia
|
South America/Mexico
|
|---|
|
IDENTITY
|
Placebo
|
291 (76.4)EE
|
162 (81.4)EE
|
37 (80.4)
|
99 (90.0)EE
|
79 (79.8)
|
79 (59.4)
|
70 (81.4)
|
|
Semagacestat 140 mg PO
|
198 (50.8)
|
129 (60.9)
|
29 (53.7)
|
69 (64.5)
|
58 (60.4)
|
69 (48.9)
|
31 (37.8)
|
|
EXPEDITION
|
Placebo
|
325 (72.1)
|
163 (76.5)
|
32 (84.2)
|
71 (87.7)
|
59 (84.3)
|
38 (61.3)
|
82 (74.6)
|
|
Solanezumab 400 mg IV
|
303 (67.8)JP
|
175 (80.7)
|
35 (76.1)
|
89 (89.0)
|
57 (87.7)
|
43 (75.4)
|
74 (77.9)
|
-
aData are presented as count (%). EE = P < 0.01 vs Eastern Europe; JP = P < 0.01 vs Japan; IV = Intravenously; PO = By mouth.
